GENETIC ANALYSIS NK -60 (8V8) - Total Assets
Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) holds total assets worth €52.45 Million EUR (≈ $61.31 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore GENETIC ANALYSIS NK -60 (8V8) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
GENETIC ANALYSIS NK -60 - Total Assets Trend (2021–2025)
This chart illustrates how GENETIC ANALYSIS NK -60's total assets have evolved over time, based on quarterly financial data. See GENETIC ANALYSIS NK -60 (8V8) shareholders funds for net asset value and shareholders' equity analysis.
GENETIC ANALYSIS NK -60 - Asset Composition Analysis
Current Asset Composition (December 2025)
GENETIC ANALYSIS NK -60's total assets of €52.45 Million consist of 59.3% current assets and 40.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 45.8% |
| Accounts Receivable | €1.91 Million | 3.6% |
| Inventory | €804.00K | 1.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how GENETIC ANALYSIS NK -60's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 8V8 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GENETIC ANALYSIS NK -60's current assets represent 59.3% of total assets in 2025, a decrease from 69.0% in 2021.
- Cash Position: Cash and equivalents constituted 45.8% of total assets in 2025, down from 55.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 29.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 3.6% of total assets.
GENETIC ANALYSIS NK -60 Competitors by Total Assets
Key competitors of GENETIC ANALYSIS NK -60 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Veracyte Inc
NASDAQ:VCYT
|
USA | $1.37 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Microba Life Sciences Ltd
AU:MAP
|
Australia | AU$43.35 Million |
|
Genetic Signatures Ltd
AU:GSS
|
Australia | AU$49.04 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
India | Rs15.07 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.41 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
GENETIC ANALYSIS NK -60 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.64 | 1.83 | 2.26 |
| Quick Ratio | 1.60 | 1.77 | 2.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €12.11 Million | €9.86 Million | €11.80 Million |
GENETIC ANALYSIS NK -60 - Advanced Valuation Insights
This section examines the relationship between GENETIC ANALYSIS NK -60's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 23.8% |
| Total Assets | €52.45 Million |
| Market Capitalization | $2.85 Million USD |
Valuation Analysis
Below Book Valuation: The market values GENETIC ANALYSIS NK -60's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: GENETIC ANALYSIS NK -60's assets grew by 23.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual total assets of GENETIC ANALYSIS NK -60 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €52.45 Million ≈ $61.31 Million |
+23.76% |
| 2024-12-31 | €42.38 Million ≈ $49.54 Million |
-20.78% |
| 2023-12-31 | €53.49 Million ≈ $62.54 Million |
-16.97% |
| 2022-12-31 | €64.42 Million ≈ $75.32 Million |
-22.84% |
| 2021-12-31 | €83.49 Million ≈ $97.61 Million |
-- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discove… Read more